BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 20231614)

  • 1. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathology consultation on myeloproliferative neoplasms.
    Schmidt AE; Oh ST;
    Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
    Anastasi J
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
    Tefferi A; Vardiman JW
    Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
    Tefferi A; Levine RL; Kantarjian H
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
    Tefferi A; Skoda R; Vardiman JW
    Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
    Mesa RA
    Curr Opin Hematol; 2008 Mar; 15(2):121-6. PubMed ID: 18300758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical aspects of myeloproliferative disorders excluding CML].
    Komatsu N
    Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
    [No Abstract]   [Full Text] [Related]  

  • 16. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
    Wadleigh M; Tefferi A
    Int J Hematol; 2010 Mar; 91(2):174-9. PubMed ID: 20191332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
    Haferlach T; Kern W; Schnittger S; Schoch C
    Ann Hematol; 2004; 83 Suppl 1():S59-61. PubMed ID: 15124674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
    Smith CA; Fan G
    Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.